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INTRODUCTION
Protamine is used in patients undergoing 
Off-pump Coronary Artery Bypass (OP-
CAB) surgery to reverse the anticoagulant 
effects of heparin and restore coagulation. 
However, protamine administration may 
produce a paradoxical anticoagulation (1) 
as recently confirmed following cardiopul-
monary bypass (CPB) surgery (2).
There are currently several schemes de-
scribed for anticoagulation with heparin 
and its reversal with protamine during OP-
CAB. The most used in European countries 
and North America is a fixed dose scheme, 
with a bolus dose of heparin established 
in IU/kg of body weight, given at the be-
ginning of the procedure, and a dose of 
protamine calculated based on the dose of 
heparin administered in a 1:1 ratio (1 mg 
of protamine for every 100 UI of heparin 
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ABSTRACT
Introduction: Currently, a dose of protamine equal to 1 mg for each 100 units of heparin given is used to reverse 
the residual heparin activity following off-pump coronary artery bypass. We hypothesized that a 1:1 ratio (ratio 
of protamine to heparin) could be higher than necessary inducing post-operative disturbance of hemostasis.
Methods: Between January and March 2014 in 9 patients undergoing off-pump coronary artery bypass, we 
evaluated the effect of a dose of protamine equal to 1 mg per 100 units of heparin (Total Calculated Dose) on 
hemostasis as evaluated by means of thromboelastomery. Two data analyses were performed: the first after the 
administration of 2/3 of the Total Calculated Dose of protamine and the second after the administration of the 
Total Calculated Dose of protamine.
Results: We found that the administration of 2/3 of Total Calculated Dose of protamine was always able to 
reverse the anticoagulant effect of heparin and that a significant clotting time elongation was induced by the 
infusion of the second part of the Total Calculated Dose of protamine. No modification in clot firmness was 
observed.
Conclusions: The present study seems to suggest that the commonly applied ratio equal to 1:1 (ratio of prot-
amine to heparin) could be higher than needed with potential and hazardous impacts on the efficacy of the 
coagulation system.
Keywords: protamine, heparin, off-pump coronary artery bypass (OPCAB), thromboelastography.
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given) (3, 4) given to reverse the residual 
heparin activity after the termination of 
anastomosis. But this scheme does not take 
into account neither the inter-patient vari-
ability nor the physiological elimination of 
the heparin and it can result in overdose or 
sub-doses of one or both drugs.
In the present study, we evaluated the mod-
ification of hemostasis induced by the ad-
ministration of the first 2/3 of the standard 
programmed dose of protamine to evaluate 
whether the full dose was really needed 
to reverse the residual heparin activity or 
rather this would result in an overdose.
METHODS
The study was carried out between January 
2014 and March 2014 at the Sassari cardio-
surgery department. 
Eligibility. Inclusion criteria were an age 
of 18 to 75 years; New York Heart Asso-
ciation class I, II, or III or an LV ejection 
fraction of at least 35 percent; ≤5 planned 
Coronary Artery Bypass Grafts; body-mass 
index (the weight in kilograms divided by 
the square of the height in meters) lower 
than 40 and a weight higher than 55 kg. 
Exclusion criteria were preoperative con-
genital or acquired disorders of hemostasis, 
acute coronary syndrome, or renal impair-
ment.
OPCAB were performed by three fully 
trained cardiac surgeons who had already 
performed a minimum of 100 off-pump op-
erations.
Anesthesia. One hour before surgery, all 
patients were treated with standard pre-
anaesthesia. Anaesthesia was then in-
duced with fentanyl, thiopental sodium 
and maintained with continuous infusion 
of propofol. Muscle relaxation was induced 
by cisatracurium (0.2 mg/kg). All patients 
received a bolus of tranexamic acid (total 
dose 30 mg/kg) following the induction of 
anesthesia. In all patients a radial artery 
line, a central venous catheter and a pul-
monary artery catheter were inserted with 
pulse oximetry, oesophageal temperature, 
urine output and capnometry continu-
ously monitored. A cell saver collection de-
vice (Cell Saver, Hemonetics Corporation, 
Braintree, MA) was always used and the 
salvaged blood was processed and re-trans-
fused following the last study-related mea-
surements. According to specific guidelines 
(5), 1 L of 0.9% saline containing 30,000 
units of heparin was mixed with aspirated 
blood at a ratio of 15 ml per 100 ml of col-
lected blood.
Heparin and Protamine Management. All 
patients were anticoagulated with 150 IU/
kg of mucosal heparin aiming at an Acti-
vated Clotting Time (ACT) of more than 
300 s. Further doses of heparin (2500 
-5000 IU) were administered intra-opera-
tively to maintain an ACT value ≥300 s as 
required. 
Anticoagulation was programmed to be re-
versed with a calculated dose of protamine 
sulfate equal to 1 mg per 100 units of total 
heparin administered, diluted in 100 ml of 
saline solution and divided in two parts. 
The first two thirds dose was administered 
directly after termination of anastomoses 
while the remaining dose was infused ten 
minutes after the initial dose. Blood sam-
ples were obtained 10 min after the first 
and the second part of the programmed 
dose of protamine and data regarding ACT, 
hematocrit, calcium ions, and thromboelas-
tomery values were collected according to 
the scheme reported in Figure 1. 
ACT was measured using the kaolin con-
taining Activated Clotting Time Plus 
Medtronic®. Blood gas analyses were per-
formed using Radiometer® ABL 800 Flex 
while thromboelastomery was evaluated 
by means of ROTEM® (Tem International 
GmbH, Munich, Germany). 
Thromboelastometry. Different variables 
and tests were taken into account to evalu-
240
Salvatore Suelzu, et al.
Heart, Lung and Vessels. 2015, Vol.7
Figure 1 - Schematic description of study procedures. TCD = Total Calculated Dose.
ate the entire coagulation and clot forma-
tion processes: 
- CT (clotting time) = time after admin-
istration of the reagent to the blood un-
til the start of clot formation. Could be 
affected either by coagulation factors 
deficiencies or to heparin or protamine 
excess.
- CFT (Clot formation time) = time from 
CT to a clot firmness of 20 mm. Primar-
ily influenced by platelet function.
- MCF (Maximum clot firmness) = the 
greatest vertical amplitude of the trace. 
It reflects the absolute strength of the fi-
brin and platelet clot. 
- A10/A20 = the clot firmness (or am-
plitude) obtained 10 or 20 minutes after 
CT. Provides a forecast on the expected 
MCF value at an earlier stage.
- INTEM = this test activates the contact 
phase of hemostasis. The result is influ-
enced by coagulation factors, platelets, 
fibrinogen and heparin. 
- HEPTEM = it represents an INTEM 
assay performed in the presence of hep-
arinase, a heparin degrading enzyme. It 
allows for the evaluation of the INTEM 
test without heparin or heparin like 
anticoagulants interferences. A differ-
ence in CT-value between HEPTEM 
and INTEM confirms the presence of 
heparin.
Primary and Secondary End Points. The pri-
mary endpoint of the study was the evalu-
ation of the effectiveness of two thirds the 
dose of protamine on heparin reversal and 
its effects on the hemostatic system. 
The secondary endpoint was the evaluation 
of the accuracy of ACT for the detection of 
heparin reversal. 
Statistical analysis. Continuous variables 
are presented as means ± SD and categori-
cal variables as proportion. Continuous 
data were analyzed using paired t-tests to 
evaluate significant changes between the 
two time points. A P value less than 0.05 
was considered significant. 
Informed consent. The study protocol has 
been approved by the Ethical Committee 
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of the Santissima Annunziata Hospital in 
Sassari. All patients gave written consent 
to participate in the study protocol before 
enrollment. 
RESULTS
Nine patients were studied. The patient 
characteristics and operative data of the 
study population are reported in Table 1. 
Anticoagulation regimens are reported in 
Table 2. Neither vasoactive nor inotropic 
drugs in the intraoperative course were 
Table 1 - Patients characteristics.
Age (yrs) 68.7±8.4
Gender (M/F) 9/0
Weight (Kg) 72.7±9.3
Height (cm) 168.5±7.9
Preoperative clopidogrel 0
Preoperative Acetyl Salicylic Acid 9
Preoperative platelet count x 103/µL 291±53
Patient with 2/3/4/5 distal anastomoses 3/5/0/1
Operation time (Skin to Skin) (min) 247.0±76.4
Heparin to protamine time (min) 112.0±21.2
Table 2 - Effect of protamine administration on thromboelastomeric parameters. 
Patinet 
N°
Weight 
(Kg)
Heparin 
Initil bolus 
(UI)*
Cumulative 
heparin
supplemental 
boluses (UI)*
Total heparin 
administered 
(UI)
Heparin 
to protamine 
time (minutes)
Total protamine 
dose program-
med (mg total) 
1 63 9500 7500 17000 101 170
2 74 11100 7500 17600 110 176
3   60 9000 5000 14000 90 140
4 80 12000 5000 17000 110 170
5 88 13200 5000 18200 106 182
6 80 12000 5000 17000 87 170
7 64 9600 10000 19600 145 196
8 70 10500 5000 15500 146 155
9 75 11300 5000 16300 1120 163
Table 3 - Anticoagulation regimen. *As required during the procedure to maintain the Activated Clotting Time 
(ACT) >300 s. All values are reported in seconds.
Paitent N° Basal ACT Higer ACT ACT 2/3 
TCD
ACT TCD CT 
Intem:Heptem 
2/3 TCD
CT 
Intem:Heptem 
TCD
1 165 348 164 170 194:198 208:232
2 192 492 168 164 192:208 240:236
3 166 378 158 146 199:203 220:250
4 169 401 194 163 204:227 213:228
5 135 339 135 137 16.186 171:191
6 141 344 133 140 191:208 237:236
7 155 301 126 130 190:195 227:245
8 154 338 136 128 172:191 178:202
9 149 298 168 168 184:202 235:232
ACT = Activated Clotting Time; TCD = Total Calculated Dose of protamine.
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used, and patients were managed in order 
to maintain normo-thermic conditions as to 
reduce biases. No patient needed red blood 
cell, platelet concentrates, fresh frozen 
plasma or administration of coagulation 
factors for intraoperative or postoperative 
bleeding. Also, no change in hematocrit, 
temperature, pH and calcium ions levels 
were observed. According to protocol, the 
total calculated dose of protamine (TCD) 
has been divided in two doses: the first, 
equal to 2/3 of the TCD, directly adminis-
tered after the termination of anastomoses 
and the remaining 1/3 infused ten minutes 
after. The effects on ACT and thromboelas-
tomeric parameters are showed in Table 
3 and 4. As shown in all cases, we found 
that the administration of 2/3 of the TCD 
was able to completely reverse the antico-
agulant effect of heparin supported by the 
evidence that all CT-HEPTEM were al-
ways found to be longer than the relative 
CT-INTEM. In the great majority of cases, 
this is even confirmed by the ACT, which 
returned to a value equal to +10% with 
respect to baseline. This is not true in case 
#4, in which the return to a value equal to 
baseline +10% was obtained only after the 
second part of the TCD, and in case #9, in 
which not even the second part of the TCD 
was able to restore a value equal to baseline 
+10%. Overall, we found a significant CT 
prolongation either in the INTEM or HEP-
TEM test (p<0.01) after the infusion of 
the second part of the TCD compared to the 
data obtained after the first part of the TCD 
with an elongation of CT-INTEM equal 
to 26.2±19.27 seconds and CT-HEPTEM 
26.0±17.3 seconds. No change in clot firm-
ness was observed.
DISCUSSION
In this observational study designed to 
evaluate whether a dose of protamine equal 
to the dose of heparin administered would 
induce anticoagulation during OPCAB, we 
found that a complete reversal of heparin 
could be effectively achieved with 2/3 of 
the dose usually proposed by the literature 
and that the current dose could be higher 
than necessary inducing post-operative dis-
turbances in hemostasis (3, 4). Moreover, 
we found that the additional administra-
tion of protamine seems to induce an elon-
gation of the clotting time with no impact 
on clot firmness. 
Our findings are in line with the results 
obtained by Gertler et al. (6) who observed 
that platelet function worsens with a prot-
amine to heparin ratio higher than 1:1 in 
blood samples taken from ten healthy vol-
Table 4 - Thromboelastomeric parameters at different stages of protamine administration. 
INTEM 
2/3 TCD
INTEM 
TCD
t-test 
p vaule
HEPTEM 2/3 
TCD
HEPTEM 
TCD
t-test 
p vaule  
CT (s) 188.1±12.0 214.0±25.0 0.0035 202.0±11.9 228.0±19.3 0.0020
CFT(s) 71.9±19.1 69.0±12.0 0.4048 64.4±15.4 66.1±9.7 0.8934
Alfa° 75.8±3.9 76.8±1.6 0.3402 76.5±3.0 76.6±1.6 0.8417 
A10(mm) 57.0±5.9 57.2±5.1 0.7458 57.9±5,8 57,8±4.9 08695
A20 (mm) 62.9±5.4 63.0±4.9 0.8548 63.7±5.5 63.1±4.9 0.4008
MCF(mm) 64.8±5.9 63.7±4.0 0.3566 64.5±5.4 64.0±5.1 0.3016
CT = Clotting Time; CFT = Clot Formation Time; α° = Alfa Angle; A10 = clot amplitude at 10 min after clotting time; 
A20 = clot amplitude at 20 min after clotting time; MCF = maximum clot firmness; TCD = Total Calculated Dose of prot-
amine; s = seconds; mm = millimeters. 
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unteers. Similar impairment of platelet ag-
gregation and function with the use of a 
protamine to heparin ratio above 2.6:1, was 
demonstrated by Carr et al. (7). 
The impact of a high protamine to heparin 
ratio on coagulation time was studied by 
Mittermayr et al. either in-vitro (8) or in 
the clinical setting (9). 
In blood samples from 26 healthy volunteers 
they found that increasing concentrations 
of protamine to a protamine to heparin ra-
tio exceeding 1.6:1 lead to an elongation of 
either the CT-INTEM or CT-HEPTEM (8). 
In a clinical setting, they studied a group 
of 22 patients with coronary artery surgery 
and cardiopulmonary bypass (CABG) (9). 
After an initial dose of protamine based 
on the total amount of heparin initially ad-
ministered, additional protamine (70 µg/
kg) was administered to patients with an 
ACT above baseline and with clinical signs 
of diffuse bleeding. In the 16 patients re-
ceiving additional protamine, coagulation 
times significantly increased. This was not 
observed in the 6 patients receiving a single 
protamine dose. 
The impact of a high protamine to heparin 
ratio was even studied by Kahn et al. (10). 
They studied blood samples of 46 patients 
undergoing cardiac surgery using CABG 
and found a significant worsening of the 
coagulation parameters using protamine to 
heparin ratio of more than 2:1.
In the clinical setting, even in absence of 
strict guidelines or recommendations, in-
traoperative anticoagulation and heparin 
reversal, is usually performed with 150 UI/
Kg initial heparin dose and 1 mg of prot-
amine per 100 units of total heparin admin-
istered respectively. 
This lead to a protamine to heparin ratio 
that is far from the ratio studied in experi-
mental setting. But, heparin levels are ex-
pected to decrease during cardiac surgery 
as the elimination half-life of heparin de-
pends either on initial dose or body tem-
perature. It could hence be expected that, 
during OPCAB a protamine regimen based 
on a fixed dose might lead to a higher than 
expected protamine to heparin ratio with a 
consequent impairment of the coagulation 
system. It has been shown that doses of 
100, 200, and 400 U/kg of intravenous hep-
arin at 37° show an approximate half-life 
of 60, 100, and 150 min, respectively (11), 
and that decreases in the body temperature 
increase the elimination half-life (12).
A decrease of heparin concentration equal 
to 40% during CPB has recently been 
shown in a randomized double-blind con-
trolled pilot study by Koster et al. (2). They 
compared the effects of two different prot-
amine management regimens on thrombo-
elastomeric parameters: heparin dose-based 
vs heparin concentration-based (assessed 
using the Hepcon MHS Plus device) prot-
amine administration. A protamine over-
dose with the inhibition of the coagulation 
process was found in the heparin dose-re-
lated group due to the reduction of the con-
centration of heparin during CPB. 
It could be expected that the expected re-
duction in heparin concentration in OP-
CAB could be higher than during CABG 
because a faster heparin turnover occurs in 
normo-thermic conditions in respect to hy-
pothermia (12). 
It is known that overdose of protamine 
has anticoagulant effects which might lead 
to bleeding complications. It causes plate-
let dysfunction (13) inhibits glycoprotein 
Ib-vWF activity (14) and serine proteases 
involved in coagulation (15) and enhances 
fibrinolysis (16). However, whether prot-
amine excess can be clinically significant 
when used to determine bleeding is an 
open question.
Despotis et al. (17) demonstrated that a 
reduction in the protamine to heparin ra-
tio reduced postoperative bleeding and the 
need for fresh frozen plasma and platelet 
administration after CPB. In a prospective 
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study of 250 patients, they found a reduc-
tion of post-operative blood, platelet, plas-
ma and cryoprecipitate units administra-
tion when protamine dose was calculated 
considering residual heparin concentration 
at the end of CPB rather than the initial 
dose administered before CPB. 
This conclusions were also confirmed in 
the study of DeLaria et al. (18). They dem-
onstrated, in a non-randomized retrospec-
tive review of 150 patients undergoing 
open heart surgery during a 9-month pe-
riod, that a reduction in protamine signifi-
cantly reduces postoperative bleeding and 
blood product administration. 
In contrast, Svenarud et al. (19) found in a 
retrospective cohort study of 300 patients 
undergoing CABG, that a single bolus dose 
of 1.3 mg protamine to 1 mg heparin is safe 
and efficient for neutralizing heparin.
They investigated 3 different protamine to 
heparin ratios: 1.3 to 1 mg vs 0.75 to 1 mg 
vs. a fractionated infusion 1+0.15+0.15 
to 1 mg. The rate of red cell transfusion 
was significantly higher in the group that 
received a protamine to heparin ratio of 
0.75 to 1 mg even in absence of differences 
in postoperative hemoglobin loss, incidence 
of resternotomy for postoperative bleeding 
and losses from mediastinal drainage. 
In our study we also evaluated the accuracy 
of ACT for the detection of heparin rever-
sal. The ACT test is a global or functional 
test that measures the effect of many vari-
ables including medications, temperature, 
dilution, coagulation factors deficiency, 
heparin anticoagulation and also prot-
amine excess. 
An ACT value higher than baseline after 
protamine administration is not always 
a sign of incomplete reversal and even an 
ACT value that has returned to baseline 
can hide residual heparin. This has been 
shown by Despotis et al. (20) who reported 
that ACT correlates poorly with plasma lev-
els of heparin during cardiac surgery. 
This seems to be confirmed in our study by 
the two patients who maintained an ACT 
over 10% of basal level after first dose of 
protamine. The hypothesis that this could 
be attributed to the need of additional doses 
of protamine could be ruled out consider-
ing the ROTEM assay CT-INTEM: CT-
HEPTEM ratio was already almost 1 after 
the first dose of protamine administered.
In absence of specific measurements, we 
cannot rule out the hypothesis that the 
CT prolongation we observed with the ad-
ministration of the second part of the total 
calculated dose of heparin could be due to 
different causes such as the presence of an-
ticoagulants or fibrin-fibrinogen degrading 
products and/or a deficit of coagulation fac-
tors. But, the absence of difference in the 
clot firmness seems to contradict this hy-
pothesis.
CONCLUSION
In the present study we found that a com-
plete reversal of heparin administered in 
patients undergoing off-pump coronary 
artery bypass could be effectively achieved 
with 2/3 of the dose usually proposed by 
the literature and that the additional ad-
ministration of protamine seems to induce 
an elongation of the clotting time with no 
imact on clot firmness. 
Future studies, specifically designed to test 
the effectiveness of different regimes in re-
versing heparin activity after OPCAB are 
needed to confirm the results of the present 
observational study. 
Moreover, the clinical impact of the CT 
thromboelastomeric test elongation and the 
duration in time of coagulation disturbance 
observed are yet to be clarified.
REFERENCES
1. Horrow JC. Protamine: a review of its toxicity. Anesth 
Anal. 1985; 64: 348-61.
2. Koster A, Börgermann J, Gummert J, Rudloff M, Zitter-
mann A, Schirmer U. Protamine overdose and its impact 
Protamine in reversing heparin during off-pump coronary bypass
245
Heart, Lung and Vessels. 2015, Vol.7
Cite this article as: Suelzu S, Cossu A, Pala G, Portoghese M, Columbanu V, Sales G, Solinas L, Brazzi L. Impact of different 
dosage of protamine on heparin reversal during off-pump coronary artery bypass: a clinical study. Heart, Lung and Vessels. 2015; 
7(3): 238-245.
Source of Support: Nil. Disclosures: None declared.
on coagulation, bleeding, and transfusions after cardio-
pulmonary bypass: results of a randomized double-blind 
controlled pilot study. Clin App Thromb Hemost. 2014; 20: 
290-5.
3. Englberger L, Streich M, Tevaearai H, Carrel T. Different 
anticoagulation strategies in off-pump coronary artery by-
pass operations: a European survey. Interact Cardiovasc 
Thorac Surg. 2008; 7: 378-82.
4. D’Ancona G, Donias HW, Karamanoukian RL, Bergsland 
J,  Karamanoukian HL. OPCAB therapy survey: off-pump 
clopidogrel, aspirin or both therapy survey. Heart Surg Fo-
rum. 2001; 4: 354-8.
5. Walters J, Shander A. Perioperative Blood Management: A 
Physicians Handbook. 2nd ed. Bethesda: American Asso-
ciation of Blood Banks. 2009; 67-9.
6. Gertler R, Wiesner G, Tassani-Prell P, Braun SL, Martin 
K. Are the point-of-care diagnostics MULTIPLATE and 
ROTEM valid in the setting of high concentrations of hepa-
rin and its reversal with protamine? J Cardiothorac Vasc 
Anesth. 2011; 25: 981-6.
7. Carr ME, Carr SL. At high heparin concentrations, prot-
amine concentrations which reverse heparin anticoagu-
lant effects are insuffi cient to reverse anti-platelet effects. 
Thrombosis Res. 1994; 75: 617-30.
8. Mittermayr M, Velik-Salchner C, Stalzer B, Margreiter J, 
Klingler A, Streif W, et al. Detection of protamine and hep-
arin after termination cardiopulmonary bypass by throm-
belastometry (ROTEM1): results of a pilot study. Anesth 
Analg. 2009; 108: 743-50.
9. Mittermayr M,  Margreiter J,  Velik-Salchner C,  Klingler 
A, Streif W, Fries D, et al.  Effects of protamine and hepa-
rin  can be  detected  and  easily  differentiated  by modifi ed 
thrombelastography (Rotem): an in vitro study. Br J An-
aesth. 2005; 95: 310-6. 
10. Khan NU, Wayne CK, Barker J, Strang T. The effects of 
protamine overdose on coagulation parameters as mea-
sured by the thrombelastograph. Eur J Anaesthesiol. 2010; 
27: 624-7.
11. Olsson P, Lagergren H, Ek S. The elimination from plasma 
of intravenous heparin: an experimental study on dogs and 
humans. Acta Med Scand. 1963; 173: 613-30. 
12. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin ther-
apy during extracorporeal circulation. II. The use of a dose 
response curve to individualize heparin and protamine dos-
age. J thorac Cardiovasc Surg. 1975; 69: 685-9. 
13. Griffi n MJ, Rinder HM, Smith BR, Tracey JB, Kriz NS, Li 
CK, et al. The effects of heparin, protamine, and heparin/
protamine reversal on platelet function under conditions of 
arterial shear stress. Anesth Analg. 2001; 93: 20-7.
14. Barstad RM, Stephens RW, Hamers MJ, Sakariassen KS. 
Protamine sulphate inhibits platelet membrane glycopro-
tein Ib-von Willebrand factor activity. Thromb Haemost. 
2000; 83: 334-7.
15. Coggin MH, Ahl R, Roland A, Beck D, Brecher AS. Prot-
amine sulfate stimulates degradation of factor Xa and the 
factor Xa-antithrombin complex. Blood Coagul Fibrinoly-
sis. 2011; 22: 247-53. 
16. Nielsen VG. Protamine enhances fi brinolysis by decreasing 
clot strength: role of tissue factor-initiated thrombin gen-
eration. Ann Thorac Surg. 2006; 81: 1720-7.
17. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufi ev A, Kater K, 
Goodnough LT, et al. The impact of heparin concentration 
and activated clotting time monitoring on blood conser-
vation. A prospective, randomized evaluation in patients 
undergoing cardiac operation. J Thorac Cardiovasc Surg. 
1995; 110: 46-54.
18. DeLaria GA, Tyner JJ, Hayes CL, Armstrong BW. Heparin 
protamine mismatch. A controllable factor in bleeding after 
open heart surgery. Arch Surg. 1994; 129: 944-50.
19. Svenarud P, Ovrum E. Clinical effects of different prot-
amine doses after cardiopulmonary bypass. Asian Cardio-
vasc Thorac Ann. 2002; 10: 119-23.
20. Despotis GJ, Summerfi eld AL, Joist JH, Goodnough LT, 
Santoro SA, Spitznagel E, et al. Comparison of activated 
coagulation time and whole blood heparin measurements 
with laboratory plasma anti-Xa heparin concentration in 
patients having cardiac operations. J Thorac Cardiovasc 
Surg. 1994; 108: -1076-82.
